ProQR Therapeutics NV (PRQR) Receives $27.20 Consensus PT from Analysts
ProQR Therapeutics NV (NASDAQ:PRQR) has earned an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $24.00.
PRQR has been the topic of a number of recent research reports. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a research note on Tuesday, September 18th. They set an “outperform” rating and a $35.00 price target on the stock. BidaskClub upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 24th. ValuEngine downgraded shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Zacks Investment Research downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, HC Wainwright set a $20.00 price target on shares of ProQR Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 9th.
Several large investors have recently modified their holdings of the company. Jennison Associates LLC boosted its stake in shares of ProQR Therapeutics by 0.6% in the 3rd quarter. Jennison Associates LLC now owns 2,998,094 shares of the biopharmaceutical company’s stock valued at $58,013,000 after purchasing an additional 16,889 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 28,025 shares in the last quarter. Ardsley Advisory Partners acquired a new stake in shares of ProQR Therapeutics in the 2nd quarter valued at $365,000. Nexthera Capital LP acquired a new stake in shares of ProQR Therapeutics in the 3rd quarter valued at $1,023,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of ProQR Therapeutics in the 3rd quarter valued at $2,129,000. Institutional investors own 30.12% of the company’s stock.
ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.10. On average, sell-side analysts anticipate that ProQR Therapeutics will post -1.38 EPS for the current fiscal year.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Featured Article: Do closed-end mutual funds pay dividends?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.